Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Axsome Therapeutics Inc (AXSM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: AXSM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $176.95
1 Year Target Price $176.95
| 14 | Strong Buy |
| 5 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.85% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.43B USD | Price to earnings Ratio - | 1Y Target Price 176.95 |
Price to earnings Ratio - | 1Y Target Price 176.95 | ||
Volume (30-day avg) 19 | Beta 0.51 | 52 Weeks Range 75.56 - 139.13 | Updated Date 08/15/2025 |
52 Weeks Range 75.56 - 139.13 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When - | Estimate -1.06 | Actual -0.97 |
Profitability
Profit Margin -49.88% | Operating Margin (TTM) -29.87% |
Management Effectiveness
Return on Assets (TTM) -21.9% | Return on Equity (TTM) -280.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5341077711 | Price to Sales(TTM) 10.96 |
Enterprise Value 5341077711 | Price to Sales(TTM) 10.96 | ||
Enterprise Value to Revenue 10.79 | Enterprise Value to EBITDA -14.81 | Shares Outstanding 49901500 | Shares Floating 38950107 |
Shares Outstanding 49901500 | Shares Floating 38950107 | ||
Percent Insiders 16.09 | Percent Institutions 76.41 |
Upturn AI SWOT
Axsome Therapeutics Inc
Company Overview
History and Background
Axsome Therapeutics Inc. was founded in 2012. It is a biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders.
Core Business Areas
- Neurology: Development and commercialization of therapies for neurological disorders, including migraine and narcolepsy.
- Psychiatry: Development and commercialization of therapies for psychiatric disorders, including depression and Alzheimer's disease agitation.
Leadership and Structure
Herriot Tabuteau, MD, is the Chief Executive Officer. The company has a board of directors and a management team focused on clinical development and commercialization.
Top Products and Market Share
Key Offerings
- AUVELITY (dextromethorphan HBr and bupropion HCl): AUVELITY is approved for the treatment of major depressive disorder (MDD) in adults. While market share data is still developing, its success depends on adoption amongst prescribers and payers. Competitors include SSRIs (e.g., sertraline, escitalopram), SNRIs (e.g., venlafaxine, duloxetine), and other atypical antidepressants.
- SUNOSI (solriamfetol): SUNOSI is approved for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA). Axsome acquired SUNOSI. Competitors include Wakix (pitolisant) and Xyrem/Xywav (sodium oxybate). Specific market share unavailable, but growing.
- AXS-05 (dextromethorphan-bupropion): Previously marketed as AUVELITY. See Above.
- AXS-07 (meloxicam-rizatriptan): AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic treatment for the acute treatment of migraine. Potential competitors: triptans (sumatriptan), gepants (rimegepant, ubrogepant), ditans (lasmiditan).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with increasing focus on CNS disorders. Market trends include the development of novel therapies and increasing patient awareness.
Positioning
Axsome is positioned as an innovator in CNS therapeutics, focusing on novel mechanisms of action and unmet medical needs. Their competitive advantage lies in their pipeline of differentiated products and their focus on specific CNS disorders.
Total Addressable Market (TAM)
The TAM for CNS disorder treatments is substantial, estimated to be worth hundreds of billions of dollars. Axsome is focused on capturing a significant share of the depression, narcolepsy, and migraine markets. TAM is estimated to be > $40 Billion.
Upturn SWOT Analysis
Strengths
- Novel product pipeline
- Approved therapies (AUVELITY, SUNOSI)
- Strong clinical data
- Experienced management team
Weaknesses
- Reliance on product pipeline success
- Commercialization risks
- Competition from established pharmaceutical companies
- Limited profitability until recently
Opportunities
- Expanding indications for existing products
- Acquiring complementary assets
- Partnering with larger pharmaceutical companies
- Addressing unmet needs in CNS disorders
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from generic drugs
- Pricing pressures from payers
Competitors and Market Share
Key Competitors
- LLY
- VRTS
- JAZZ
- TEVA
Competitive Landscape
Axsome's advantages include novel therapies and a focused CNS strategy. Disadvantages include competition from larger, more established pharmaceutical companies.
Major Acquisitions
SUNOSI
- Year: 2022
- Acquisition Price (USD millions): 583
- Strategic Rationale: Expanded Axsome's portfolio in the sleep disorder market and added a commercialized product with existing revenue stream.
Growth Trajectory and Initiatives
Historical Growth: Axsome's historical growth has been driven by clinical trial success and regulatory approvals. Growth has been rapid but volatile.
Future Projections: Future growth is dependent on the commercial success of AUVELITY and SUNOSI, as well as the development of other pipeline products. Analyst estimates vary.
Recent Initiatives: Recent initiatives include the commercial launch of AUVELITY, acquisition of SUNOSI, and continued clinical development of other pipeline assets.
Summary
Axsome Therapeutics is a growing biopharmaceutical company with a focus on CNS disorders and two products on the market. The successful commercialization of AUVELITY and SUNOSI are crucial for its future financial performance. Continued success with its pipeline and managing competition will also be key for success. Axsome needs to manage its debt and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Axsome Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Axsome Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2015-11-19 | Founder, Chairman, CEO & President Dr. Herriot Tabuteau M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 846 | Website https://www.axsome.com |
Full time employees 846 | Website https://www.axsome.com | ||
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.